Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • Notes From B Riley 13th Annual Investor Conference: CEMI,VRML 0 comments
    May 24, 2012 3:43 PM | about stocks: VRML, CEMI

    There were some excellent small cap companies presenting at the B. Riley Investor Conference in Santa Monica this week. Five tracks covered companies in healthcare, technology and energy, consumer/telecom, software and services and internet and media. Our focus within healthcare is biotechnology, tools and clinical diagnostics.

    Micro-Cap Plays in Clinical Diagnostics

    Chembio (CEMI.PK $0.52) Market Cap $34M Cash $2.95M

    Chembio is an emerging growth player in point-of-care (POC) diagnostics with a focus in infectious disease with rapid tests for HIV 1&2, tuberculosis and syphilis with 2011 revenues of $19.4M. Total revenues for Q1 2012 of $6.65 M are on track for growth with operating income of $720k compared to a loss last year of $139k. Forecasted revenues for 2012 are $24.4M. A new "dual path" test platform called the DPP HIV 1&2 has begun a 3000 patient clinical trials that can be used with finger stick, oral whole blood or plasma. The market potential for HIV POC testing is $200M WW. Alere (ALR $18.50) is their marketing partner with revenues of $7.2M and Alere also holds an 8% equity position in the Company. Recently a competitive product from Orasure (OSUR $10.55) made headlines when the FDA recommended that their OraQuik HIV In-Home test based on a moth swab be approved. A big opportunity for the future is an HCV test with a POC potential of $250M. Over a one year period the shares are stable up 7.28%. Management holds 12.3% of the shares.

    Vermillion (VRML $2.49) Market Cap $33.42 Cash $15.5M

    VRML stock soared 36% today on high volume after yesterday's B. Riley presentation with no apparent news except a lot of " mentions" from small cap newsletters. Gail Page the ex-CEO presented an update of the Company with a focus on the OVA-1 FDA approved clinical biomarker test (multimarker IVDMIA) for ovarian masses that would replace a very old CA-125 test. 3952 OVA-1 tests were sold in Q1 2012 with a forecast of 4300 for Q2. The Company has a revenue sharing agreement with Quest (DGX $57) but has 10 reps of their own supporting the Quest sales effort. A second product is under development called Vasclir Ova-2 a biomarker for identifying high risk populations for PAD (peripheral arterial diseases) utilizing beta-2 microglobulin with preliminary data expected in June.

    see Face-off BGMD vs VRML

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: VRML, CEMI
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.